No Data
Featured announcements | Kanzhun revenue increased 19% year-on-year in the third quarter; China Taibao's original premium income during the year exceeded 410 billion yuan
Xinyi Glass and Xinyi Auto Glass (Hong Kong) signed a 2024 glass supply agreement; CGN Energy completed a cumulative total of 17,684.1 gigawatt-hours of power generation in the first 11 months, an increase of 1.7% over the previous year.
IMMUNOTECH-B (06978.HK): CAR-T-19 injection has been granted breakthrough therapy designation.
On December 11, Gelonghui announced that IMMUNOTECH-B (06978.HK) has released a statement indicating that the group's product CAR-T–19 injection (a type of anti-CD19 single-chain antibody chimeric antigen receptor T cell injection) has been granted breakthrough therapy designation by the National Medical Products Administration's Drug Evaluation Center for the treatment of patients aged 25 and younger with relapsed/refractory B-cell acute lymphoblastic leukemia ("B-ALL"). This designation is based on reliable clinical efficacy and safety data for CAR-T–19 injection. It will expedite the clinical development of CAR-T–19 injection and accelerate its availability for patients.
Express News | Immunotech Biopharm - CAR-T-19 Injection Granted Breakthrough-Therapy Designation by Nmpa China
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Eternal Bio-B (06978.HK): Liang Ruibing appointed as authorized representative.
Great Wisdom Report December 2nd | Yongtai Life Sciences - B (06978.HK) announced that Chen Ran has resigned as joint company secretary and authorized representative for other business responsibilities, effective from December 2, 2024. The company's other current joint company secretary, Liang Ruibing, a person qualified and experienced under Listing Rule 3.28 as company secretary, will continue to serve and act as the company's sole company secretary. Liang Ruibing has been appointed as an authorized representative, effective from December 2, 2024.
